智通财经APP获悉，4月3日，中国国家药监局药品审评中心(CDE)官网最新公示，阿斯利康(AZN.US)申报的本瑞利珠单抗注射液一项新适应症上市申请获得受理，具体适应症尚未披露。公开资料显示，本瑞利珠单抗(benralizumab)是阿斯利康开发的一款靶向IL-5受体的单克隆抗体，此前已经在中国获批用于成人和12岁及以上青少年重度嗜酸粒细胞性哮喘的维持治疗。在美国，该产品还已经获FDA批准用于治疗嗜酸性肉芽肿性多血管炎(EGPA)的成年患者。

截图来源：CDE官网

根据阿斯利康近期新闻稿介绍，本瑞利珠单抗重度嗜酸粒细胞性哮喘(SEA)适应症目前已在美国、欧盟、日本、中国等80多个国家和地区获批。嗜酸性肉芽肿病伴多血管炎(EGPA)适应症也已经在美国、欧盟和日本等全球35多个国家和地区获批。阿斯利康也在对该产品的其它适应症进行开发，包括慢性阻塞性肺疾病(COPD)和嗜酸粒细胞增多综合征。本次本瑞利珠单抗新适应症在中国申报上市，意味着其有望在不久的将来惠及更多患者。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.